3 abstracts to be presented at International Cancer meeting in Boston
Oncology Venture announces that three abstracts have been accepted for presentation on the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics in November 5-9 2015, Hynes Convention Center, Boston, Massachusetts.
“Oncology Ventures in-licensed DRP™ - Drug Response Predictor matching the cancer drug to the responding patient has gained considerable interest from experts. The presentation of three abstracts at this well recognized international high level cancer conference is very encouraging for Oncology Ventures use of DRP™ in precision medicine” said CEO, MD, PhD, Professor of Clinical Oncology Peter Buhl Jensen
Abstract Number: A182
Title: Targeting the topoisomerase 1 enzyme in cancer cells with acquired resistance to SN-38
Session ID: Poster Session A
Session Title: Topoisomerase Inhibitors
Session Date and Time: Friday Nov 6, 2015 12:15 PM - 3:15 PM
Location: Exhibit Hall C-D
Abstract Number: B71
Title: DEN-50R - establishment of a novel and unique cell line based drug screening platform for cancer treatment
Session ID: Poster Session B
Session Title: Drug Screening
Session Date and Time: Saturday Nov 7, 2015 12:30 PM - 3:30 PM
Location: Exhibit Hall C-D
Abstract Number: C168
Title: A two stage prospective clinical trial with irofulven treatment targeting a selected subgroup of castration- and docetaxel resistant prostate cancer patients
Session ID: Poster Session C
Session Title: Therapeutic Agents: Biological
Session Date and Time: Sunday Nov 8, 2015 12:30 PM - 3:30 PM
Location: Exhibit Hall C-D
For further information concerning Oncology Venture please contact:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. The business enterprise is based on “rescuing” anti-cancer drugs whose development has been interrupted in the clinical development stage. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 26 of the 32 clinical studies that were examined.
The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
Tags: